<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752646</url>
  </required_header>
  <id_info>
    <org_study_id>ALC-15417759</org_study_id>
    <nct_id>NCT02752646</nct_id>
  </id_info>
  <brief_title>Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%</brief_title>
  <official_title>Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDbackline, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MDbackline, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs
      ketorolac 0.5% among patients undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, prospective, controlled, open-label study, comparing the
      tolerability and toxicity of two commercially available non-steroidal anti-inflammatory eye
      drops, nepafenac 0.3% and ketorolac 0.5% (generic formulation). The study will involve one
      eye of each subject. The study will follow good clinical practices (GCP). The primary outcome
      measure will be tolerability of the study medication as measured by the eye drop comfort
      survey instrument.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of nepafenac vs ketorolac</measure>
    <time_frame>14-28 days</time_frame>
    <description>Patients will fill out a survey describing eye drop tolerability at 14-28 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>nepafenac 0.3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketorolac 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nepafenac 0.3%</intervention_name>
    <description>Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.</description>
    <arm_group_label>nepafenac 0.3%</arm_group_label>
    <other_name>Ilevro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketorolac</intervention_name>
    <description>Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.</description>
    <arm_group_label>ketorolac 0.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years and older currently undergoing femtosecond or manual cataract
             surgery with or without astigmatic keratotomy.

          2. Patients willing to take an electronic survey about their tolerability of either study
             medication.

        Exclusion Criteria

          1. Active, systemic or local disease condition that causes clinically significant ocular
             surface irritation such that it could interfere with the questions in the survey and
             examination findings.

          2. Any of the following ocular (eye or eyelid) conditions in either eye within 1 Months
             prior to the enrollment visit:

               1. Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgery
                  procedure.

               2. Clinically significant ocular trauma.

               3. Active ocular Herpes simplex or Herpes zoster (eye or eyelid) infection.

               4. Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis,
                  conjunctivitis)

               5. Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal
                  infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids
                  including hordeolum/stye)

          3. Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis

          4. Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis,
             staphylococcal blepharitis or seborrheic blepharitis)

          5. Eyelid abnormalities that significantly affect lid function (e.g., entropion,
             ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe
             ptosis)

          6. Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical
             burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal
             fluorescein staining, or map dot fingerprint dystrophy)

          7. Participation in another ophthalmic clinical trial involving a therapeutic drug or
             device within 30 days prior to the distribution of the survey

          8. Participation in this trial in the same patient's fellow eye.

          9. Patients who are pregnant or breastfeeding or who may become pregnant during
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Hovanesian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Jules Stein Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. Review.</citation>
    <PMID>16196117</PMID>
  </results_reference>
  <results_reference>
    <citation>Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003 Oct;22(7):640-50. Review.</citation>
    <PMID>14508260</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make individual patient data available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

